We expected miracles—what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

According to recent reporting, Gov. Josh Shapiro is considering cutting off access to the weight loss drugs like Zepbound and Wegovy to all Medicaid recipients in the state who are not dangerously ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

The legal process will see $1.15bn (£860mn) of the 60-year-old diet brand's debt written off while it agrees new terms for ...

Diageo's share price has dropped 15.3% in the year to date. Could it be about to become one of the FTSE 100's best recovery ...

Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved ...

Weight Watchers, the brand built on providing support for people who are trying to lose weight, filed for bankruptcy protection. The company is burdened with debt as more customers turn to medication.